Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines

Rifampicin-resistant (RR) tuberculosis (TB) in children is a major global health concern but is often neglected in economics research. Accurate cost estimations across the spectrum of paediatric RR-TB treatment regimens are critical inputs for prioritisation and budgeting decisions, and an existing...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2024-07, Vol.19 (7), p.e0305930
Hauptverfasser:	Wilkinson, Thomas, Garcia-Prats, Anthony J, Sachs, Tina, Paradkar, Mandar, Suryavanshi, Nishi, Kinikar, Aarti, Frias, Melchor V, Sinanovic, Edina, Hesseling, Anneke C, Seddon, James A, Palmer, Megan
Format:	Artikel
Sprache:	eng
Schlagworte:	Acceptability Adolescent Adolescents Age Antitubercular Agents - economics Antitubercular Agents - therapeutic use Child Child, Preschool Children Children & youth Cost analysis Cost assessments Cost benefit analysis Costs Disease resistance Drug Costs Drug dosages Female Global health Health aspects Health services HIV Human immunodeficiency virus Humans India Infant Male Medical economics Medicine Medicine and Health Sciences Palatability Pediatrics People and places Pharmaceuticals Pharmacokinetics Philippines Prices Public health Purchasing power parity Rifampin Rifampin - economics Rifampin - therapeutic use Social Sciences South Africa Teenagers Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!